IM Therapeutics is developing a personalized, orally available small molecule therapeutic for diabetes. This is a milestone for autoimmune diseases and may be the first time diabetes patients can be preselected for a therapeutic based on whether they carry a specific gene.
The pill is designed for patients with the HLA-DQ8 gene. It has the potential to extend diabetes patients’ “honeymoon” when their insulin activity is still reasonably high. Known as IMT-002, the drug molecule may not yet eliminate the need for insulin injections, but developers say it may notably lengthen the time people can go without adjusting insulin doses.Read More